Molecular Pathways: Fumarate Hydratase-Deficient Kidney Cancer—Targeting the Warburg Effect in Cancer
- 30 June 2013
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (13), 3345-3352
- https://doi.org/10.1158/1078-0432.ccr-13-0304
Abstract
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a hereditary cancer syndrome in which affected individuals are at risk for development of cutaneous and uterine leiomyomas and an aggressive form of type II papillary kidney cancer. HLRCC is characterized by germline mutation of the tricarboxylic acid (TCA) cycle enzyme, fumarate hydratase (FH). FH-deficient kidney cancer is characterized by impaired oxidative phosphorylation and a metabolic shift to aerobic glycolysis, a form of metabolic reprogramming referred to as the Warburg effect. Increased glycolysis generates ATP needed for increased cell proliferation. In FH-deficient kidney cancer, levels of AMP-activated protein kinase (AMPK), a cellular energy sensor, are decreased resulting in diminished p53 levels, decreased expression of the iron importer, DMT1, leading to low cellular iron levels, and to enhanced fatty acid synthesis by diminishing phosphorylation of acetyl CoA carboxylase, a rate-limiting step for fatty acid synthesis. Increased fumarate and decreased iron levels in FH-deficient kidney cancer cells inactivate prolyl hydroxylases, leading to stabilization of hypoxia-inducible factor (HIF)-1α and increased expression of genes such as VEGF and glucose transporter 1 (GLUT1) to provide fuel needed for rapid growth demands. Several therapeutic approaches for targeting the metabolic basis of FH-deficient kidney cancer are under development or are being evaluated in clinical trials, including the use of agents such as metformin, which would reverse the inactivation of AMPK, approaches to inhibit glucose transport, lactate dehydrogenase A (LDHA), the antioxidant response pathway, the heme oxygenase pathway, and approaches to target the tumor vasculature and glucose transport with agents such as bevacizumab and erlotinib. These same types of metabolic shifts, to aerobic glycolysis with decreased oxidative phosphorylation, have been found in a wide variety of other cancer types. Targeting the metabolic basis of a rare cancer such as FH-deficient kidney cancer will hopefully provide insights into the development of effective forms of therapies for other, more common forms of cancer. Clin Cancer Res; 19(13); 3345–52. ©2013 AACR.Keywords
This publication has 56 references indexed in Scilit:
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us?Cell, 2012
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012
- Chlorinated Englerins with Selective Inhibition of Renal Cancer Cell GrowthJournal of Natural Products, 2012
- Reductive carboxylation supports growth in tumour cells with defective mitochondriaNature, 2011
- Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 SignalingCancer Cell, 2011
- The Glycolytic Shift in Fumarate-Hydratase-Deficient Kidney Cancer Lowers AMPK Levels, Increases Anabolic Propensities and Lowers Cellular Iron LevelsCancer Cell, 2011
- Cysteine-based regulation of the CUL3 adaptor protein Keap1Toxicology and Applied Pharmacology, 2010
- UOK 262 cell line, fumarate hydratase deficient (FH−/FH−) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancerCancer Genetics and Cytogenetics, 2010
- Englerin A, a Selective Inhibitor of Renal Cancer Cell Growth, from Phyllanthus engleriOrganic Letters, 2008